Búsqueda | Biblioteca Virtual en Salud

Van Rompay, K K; Cherrington, J M; Marthas, M L; Berardi, C J; Mulato, A S; Spinner, A; Tarara, R P; Canfield, D R; Telm, S; Bischofberger, N; Pedersen, N C.

Antimicrob Agents Chemother ; 40(11): 2586-91, 1996 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-8913470

16.

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay, K K; Miller, M D; Marthas, M L; Margot, N A; Dailey, P J; Canfield, D R; Tarara, R P; Cherrington, J M; Aguirre, N L; Bischofberger, N; Pedersen, N C.

J Virol ; 74(4): 1767-74, 2000 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10644348

17.

A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Lohman, B L; McChesney, M B; Miller, C J; McGowan, E; Joye, S M; Van Rompay, K K; Reay, E; Antipa, L; Pedersen, N C; Marthas, M L.

J Virol ; 68(11): 7021-9, 1994 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-7933084

18.

Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

van Rompay, K K; Dailey, P J; Tarara, R P; Canfield, D R; Aguirre, N L; Cherrington, J M; Lamy, P D; Bischofberger, N; Pedersen, N C; Marthas, M L.

J Virol ; 73(4): 2947-55, 1999 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-10074144

19.

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay, K K; Cherrington, J M; Marthas, M L; Lamy, P D; Dailey, P J; Canfield, D R; Tarara, R P; Bischofberger, N; Pedersen, N C.

Antimicrob Agents Chemother ; 43(4): 802-12, 1999 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-10103184

20.

Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.

Van Rompay, K K; Berardi, C J; Dillard-Telm, S; Tarara, R P; Canfield, D R; Valverde, C R; Montefiori, D C; Cole, K S; Montelaro, R C; Miller, C J; Marthas, M L.

J Infect Dis ; 177(5): 1247-59, 1998 May.

Artículo en Inglés | MEDLINE | ID: mdl-9593009

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.

Antiretroviral drug trials.

Attenuated retrovirus vaccines and AIDS.

Prophylactic ZDV dosing frequency in macaques.

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.

Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques.

Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251.

Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus.

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.

Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection.

Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac.

9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.